{"id":"pneumovax-ii","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site pain"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL20226","moleculeType":"Protein","molecularWeight":"782.90"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the administration of inactivated pneumococcal polysaccharides, which are recognized by the immune system as foreign and trigger an immune response. This response leads to the production of antibodies that can recognize and bind to the polysaccharide capsule of S. pneumoniae, thereby preventing the bacteria from causing disease.","oneSentence":"Pneumovax II stimulates the immune system to produce antibodies against Streptococcus pneumoniae.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:25.610Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae in adults 50 years of age and older"}]},"trialDetails":[{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT06736041","phase":"PHASE3","title":"Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-18","conditions":"Pneumococcal Immunization","enrollment":1714},{"nctId":"NCT07418372","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2026-03-12","conditions":"Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus, Diphtheria","enrollment":660},{"nctId":"NCT05183854","phase":"PHASE2","title":"Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial","status":"RECRUITING","sponsor":"University of Utah","startDate":"2022-01-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":60},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT07333352","phase":"PHASE2","title":"PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months","status":"RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2025-09-11","conditions":"Pneumococcal Infectious Disease","enrollment":480},{"nctId":"NCT05417165","phase":"PHASE2","title":"Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Seema Bhat","startDate":"2023-09-29","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":80},{"nctId":"NCT07300644","phase":"PHASE2","title":"Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-11-25","conditions":"Pneumococcal Infectious Disease","enrollment":420},{"nctId":"NCT06678620","phase":"PHASE2","title":"Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2024-04-20","conditions":"Pneumococcal Infectious Disease","enrollment":992},{"nctId":"NCT01351896","phase":"PHASE2","title":"Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-11-02","conditions":"Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia","enrollment":49},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT03376477","phase":"PHASE2","title":"Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-09-23","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT00505063","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07-10","conditions":"Childhood Cancer, Multiple Diseases","enrollment":76},{"nctId":"NCT03035331","phase":"PHASE1, PHASE2","title":"Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-08-15","conditions":"Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":11},{"nctId":"NCT06708286","phase":"PHASE2, PHASE3","title":"A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-12-20","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1820},{"nctId":"NCT04080531","phase":"PHASE4","title":"Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-10-18","conditions":"Plasma Cell Neoplasm","enrollment":165},{"nctId":"NCT05084508","phase":"PHASE2","title":"A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-02-03","conditions":"Chickenpox","enrollment":800},{"nctId":"NCT06703203","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2024-08-27","conditions":"Pneumococcal Vaccines","enrollment":450},{"nctId":"NCT03098628","phase":"PHASE2, PHASE3","title":"Trial of Simplified Pneumococcal Vaccination in Vietnam II","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2017-03-08","conditions":"Pneumococcal Vaccine","enrollment":2501},{"nctId":"NCT06698198","phase":"PHASE1","title":"Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-03","conditions":"Pneumococcal Immunization","enrollment":175},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT03893448","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-19","conditions":"Pneumococcal Infections, Pneumococcal Vaccines","enrollment":1720},{"nctId":"NCT00566098","phase":"PHASE1, PHASE2","title":"Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-11","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":26},{"nctId":"NCT04016714","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-08-28","conditions":"Pneumococcal Infections","enrollment":1191},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT00858728","phase":"NA","title":"Effect of Fruit and Vegetable Consumption on Immune Function in the Elderly","status":"COMPLETED","sponsor":"Queen's University, Belfast","startDate":"2006-10","conditions":"Immune Function","enrollment":83},{"nctId":"NCT01312389","phase":"PHASE1, PHASE2","title":"A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"TERMINATED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2011-04","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":3},{"nctId":"NCT02482636","phase":"PHASE2","title":"Baby Vaccine Study (Sched3)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Infectious Diseases","enrollment":189},{"nctId":"NCT02309515","phase":"PHASE2","title":"Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-06-11","conditions":"Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia","enrollment":12},{"nctId":"NCT01681992","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-10","conditions":"Measles, Mumps, Rubella","enrollment":4538},{"nctId":"NCT02184572","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-25","conditions":"Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine","enrollment":1742},{"nctId":"NCT01245673","phase":"PHASE2","title":"Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2011-05-10","conditions":"Myeloma","enrollment":28},{"nctId":"NCT00861744","phase":"PHASE2","title":"Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-03","conditions":"Rubella, Mumps, Measles","enrollment":1259},{"nctId":"NCT00609492","phase":"PHASE3","title":"Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01-03","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":245},{"nctId":"NCT01702428","phase":"PHASE3","title":"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-09","conditions":"Rubella, Measles, Mumps","enrollment":5016},{"nctId":"NCT00046852","phase":"PHASE1, PHASE2","title":"Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2001-12","conditions":"Infection, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT00834665","phase":"PHASE1","title":"Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2006-12","conditions":"Multiple Myeloma","enrollment":59},{"nctId":"NCT02987972","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-21","conditions":"Pneumococcal Infections","enrollment":1051},{"nctId":"NCT03467984","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2018-05-25","conditions":"Pneumococcal Infection","enrollment":230},{"nctId":"NCT02037984","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-01-28","conditions":"Streptococcus Pneumoniae Infection, Pneumococcal Infections","enrollment":341},{"nctId":"NCT02531373","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-15","conditions":"Pneumococcal Infections","enrollment":338},{"nctId":"NCT00496015","phase":"PHASE3","title":"Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-02","conditions":"Infections, Streptococcal","enrollment":750},{"nctId":"NCT00513409","phase":"PHASE2","title":"Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-22","conditions":"Infections, Streptococcal","enrollment":163},{"nctId":"NCT00390910","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-01","conditions":"Infections, Streptococcal","enrollment":286},{"nctId":"NCT00127855","phase":"PHASE2","title":"Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":409},{"nctId":"NCT00289783","phase":"PHASE3","title":"Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-22","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4441},{"nctId":"NCT00134719","phase":"PHASE2","title":"Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04-11","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":1104},{"nctId":"NCT00569309","phase":"NA","title":"Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2007-12-12","conditions":"Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Small Intestine Cancer","enrollment":30},{"nctId":"NCT00282308","phase":"PHASE2","title":"A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-01-23","conditions":"Rheumatoid Arthritis","enrollment":103},{"nctId":"NCT00327665","phase":"PHASE1","title":"Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-01","conditions":"Infections, Streptococcal","enrollment":335},{"nctId":"NCT00169481","phase":"PHASE2","title":"A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10","conditions":"Streptococcal Infections","enrollment":689},{"nctId":"NCT00345683","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4021},{"nctId":"NCT00307567","phase":"PHASE2","title":"Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11","conditions":"Acellular Pertussis, Tetanus, Hepatitis B","enrollment":689},{"nctId":"NCT00729001","phase":"PHASE2","title":"Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-11","conditions":"Infections, Rotavirus","enrollment":529},{"nctId":"NCT01339000","phase":"PHASE2","title":"Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-04","conditions":"Breast Cancer, Colon Cancer, Bladder Cancer","enrollment":1},{"nctId":"NCT00422292","phase":"PHASE3","title":"Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-12","conditions":"Meningococcal Meningitis, Measles, Mumps","enrollment":1664},{"nctId":"NCT01489618","phase":"PHASE2","title":"\"Prime Boost\" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency","status":"TERMINATED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-06","conditions":"Common Variable Immunodeficiency","enrollment":45},{"nctId":"NCT00741039","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-08","conditions":"Breast Cancer, Lung Cancer, Prostate Cancer","enrollment":126},{"nctId":"NCT01432158","phase":"PHASE3","title":"Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-01","conditions":"Pneumococcal Disease","enrollment":4},{"nctId":"NCT00445484","phase":"PHASE2","title":"Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-01","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":22},{"nctId":"NCT00488683","phase":"PHASE2","title":"B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Disease","enrollment":216},{"nctId":"NCT00262002","phase":"PHASE2","title":"Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2004-09","conditions":"Prevention of Meningococcal Disease","enrollment":601},{"nctId":"NCT01000311","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-11","conditions":"Meningococcal Disease","enrollment":529},{"nctId":"NCT00499577","phase":"PHASE1, PHASE2","title":"Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"University of Maryland Greenebaum Cancer Center","startDate":"2006-12","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":56},{"nctId":"NCT00307008","phase":"PHASE2","title":"Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Streptococcus Pneumoniae Vaccines","enrollment":1198},{"nctId":"NCT00205803","phase":"PHASE1, PHASE2","title":"Study Evaluating Pneumococcal Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2004-09","conditions":"Healthy Subjects, Pneumococcal Infections","enrollment":249},{"nctId":"NCT00570999","phase":"PHASE2","title":"Palifermin After Haploidentical PBSCT","status":"WITHDRAWN","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2008-02","conditions":"Non-Hodgkin's Lymphoma or Hodgkin's Disease, Acute Leukaemia, Myelodysplastic Syndrome","enrollment":""},{"nctId":"NCT00269672","phase":"PHASE2","title":"Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-09","conditions":"Vaccines, Pneumococcal Conjugate Vaccine","enrollment":915},{"nctId":"NCT00679159","phase":"PHASE2","title":"A Study of MVA85A in Healthy Children and Infants","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2008-02","conditions":"Tuberculosis","enrollment":168},{"nctId":"NCT00170612","phase":"PHASE2","title":"Pneumococcal Vaccination of Fiji Infants","status":"COMPLETED","sponsor":"University of Melbourne","startDate":"2005-11","conditions":"Pneumococcal Infections","enrollment":552},{"nctId":"NCT00327522","phase":"PHASE2","title":"Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06","conditions":"Prophylactic Pneumococcal Diseases","enrollment":10}],"_emaApprovals":[],"_faersSignals":[{"count":12,"reaction":"HYPOGAMMAGLOBULINAEMIA"},{"count":12,"reaction":"IMMUNODEFICIENCY"},{"count":11,"reaction":"TREMOR"},{"count":10,"reaction":"FEELING OF BODY TEMPERATURE CHANGE"},{"count":10,"reaction":"FOOD INTERACTION"},{"count":10,"reaction":"HYPERHIDROSIS"},{"count":10,"reaction":"MENTAL DISORDER"},{"count":10,"reaction":"TEARFULNESS"},{"count":8,"reaction":"FOETAL DISTRESS SYNDROME"},{"count":7,"reaction":"DRUG INTERACTION"}],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pneumovax II","genericName":"Pneumovax II","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Biologic","firstApprovalDate":"","aiSummary":"Pneumovax II is a protein-based vaccine that targets Streptococcus Pneumoniae. It is used to prevent infections caused by Streptococcus Pneumoniae, as indicated by its study in ClinicalTrials.gov for conditions such as Infections and Streptococcal infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}